This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
Accept
Decline
Press Releases
2026.11.16

Acepodia Advances Liver Cancer Candidate ACE723 with First Patient Dosed in Phase 1 Trial Across the U.S., China and Taiwan

Board approves an R&D resource-focus strategy that makes the Antibody Dual-Drug Conjugate (AD2C) platform the core of the company’s development

Acepodia (6976) today announced that its Board of Directors has approved an R&D resource-focus strategy. Going forward, the company will build on its Antibody Dual-Drug Conjugate (AD2C) platform and devote its full resources to advancing ACE723, an antibody dual-drug conjugate for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

ACE723: Advancing in Parallel Across the U.S., China and Taiwan

ACE723 received regulatory clearance to begin a Phase 1 clinical trial in the U.S. and China in September 2026 and in Taiwan in October 2026, and the first patient was dosed this month (November). ACE723 is the first drug candidate developed on the AD2C platform to enter clinical trials in humans. The Phase 1 trial will evaluate the safety, tolerability, dose-limiting toxicities, pharmacokinetics and preliminary anti-tumor activity of ACE723, and establish the recommended dose for further development.

Liver Cancer: Limited Options in Advanced Disease and an Urgent Medical Need

ACE723 is being developed for the treatment of unresectable or metastatic HCC. HCC accounts for more than 70% of primary liver cancer cases and is a common, highly lethal cancer worldwide, with a five-year survival rate of only about 22%. For patients with advanced disease that cannot be surgically removed or has spread, the current first-line standard of care is based on immunotherapy combinations, including an immune checkpoint inhibitor combined with an anti-angiogenic agent, or dual immunotherapy. However, once first-line treatment fails or patients develop resistance, there is no standard second-line therapy supported by robust evidence. Treatment options are very limited, the disease often continues to progress, and a significant unmet medical need remains.

HCC is especially prevalent in Asia, and the number of patients worldwide continues to grow. Liver cancer is the third leading cause of cancer death globally. According to the global cancer statistics report published by the American Cancer Society (ACS) in July 2026, based on GLOBOCAN data from the International Agency for Research on Cancer (IARC), there were approximately 843,000 new cases of liver cancer and 732,000 deaths from liver cancer worldwide in 2024.

According to market forecasts from Datamonitor Healthcare, the HCC drug market across the seven major pharmaceutical markets (7MM: the U.S., Japan and the five major European countries) is expected to grow from about US$2.4 billion in 2026 to about US$2.9 billion in 2030. Developing innovative drugs with novel mechanisms of action has become an urgent clinical need, with considerable market potential.

ACE723: One Antibody, Two Drugs
ACE723 is a novel antibody dual-drug conjugate developed on the company’s proprietary AD2C platform. It targets GPC3, a protein highly expressed in 70% to 90% of HCC cases but rarely expressed in normal tissue. No GPC3-targeted antibody-drug conjugate has yet been approved anywhere in the world. Unlike conventional ADCs that carry a single cytotoxic payload, ACE723 uses the specificity of the antibody to deliver two chemotherapy drugs with different mechanisms of action to tumor cells at the same time. This design aims to overcome tumor heterogeneity and the drug resistance that a single chemotherapy agent may face.
In preclinical research presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, the anti-GPC3 AD2C candidate showed binding affinity and internalization comparable to the parent antibody, supporting its advancement into clinical development. Through ACE723’s novel mechanism of action, which differs from current therapies, the company aims to offer a next-generation treatment option for patients with advanced liver cancer and help close the existing treatment gap.

Building on Core Technology, Focusing on Antibody Therapeutics

Like the company’s earlier cell conjugation technology, the AD2C platform originates from the bioorthogonal chemistry research of Nobel Laureate in Chemistry Carolyn Bertozzi. This strategic adjustment concentrates the core capabilities the company has built in bioorthogonal conjugation chemistry on antibody-drug conjugates. AD2C can attach two different drugs to the same antibody without requiring antibody engineering.

Concentrating Resources on the Most Promising Programs

To concentrate resources on advancing ACE723 and the AD2C platform, the Board also resolved to end development of cell therapy products ahead of schedule. This decision takes into account the rapid development of new technologies such as in vivo CAR-T, as well as changes in the capital environment of the global cell therapy industry. In line with this adjustment, the company will close the Phase 1/2 trial ACE1831-201 early; data obtained from the trial to date have shown no safety concerns. The company will also terminate early its related patent license agreement with Lawrence Berkeley National Laboratory (LBNL) in the U.S. Under the terms of the agreement, no termination fee or compensation is payable, and there is no material impact on the company’s finances or business.

“Liver cancer is one of the heaviest cancer burdens for patients in Asia, and patients with advanced disease still have very few options once existing treatments stop working,” said Dr. Sonny Hsiao, Chairman and CEO of Acepodia. “ACE723 secured clinical clearance in the U.S., China and Taiwan within two months, and the first patient has now been dosed. From here, we will concentrate our resources and people on ACE723 and the AD2C platform, and let clinical progress prove this direction.”